Optometry Times Staff Reports

This latest approval for Beovu (brolucizumab) 6 mg is the second indication granted by the EC, as it was first approved in 2020 for the treatment of AMD.

An exciting line-up of speakers and panelists is promised for the main-stage destination at VEE 2022.

Approved by the FDA last October, XIPERE (triamcinolone acetonide injectable suspension) was approved by the FDA last October as the first and only therapy for treating macular edema associated with uveitis.

US commercialization of EVO will begin immediately in select cities across the country.

The latest launches of BRIO-I and BRIO-II follow promising topline data from the phase 2 VIVD clinical study evaluating Brimochol PF.

With its portable capabilities, the Heru platform replaces legacy diagnostic devices and surpasses standard care in cost and size.